guest ::
| Home > Publications database > Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case-Control Analysis Within the EPIC Study. > print |
| Home > Publications database > Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case-Control Analysis Within the EPIC Study. > print |
| 001 | 295915 | ||
| 005 | 20241222014524.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers16234116 |2 doi |
| 024 | 7 | _ | |a pmid:39682302 |2 pmid |
| 024 | 7 | _ | |a altmetric:172178595 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02728 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Almanza-Aguilera, Enrique |b 0 |
| 245 | _ | _ | |a Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case-Control Analysis Within the EPIC Study. |
| 260 | _ | _ | |a Basel |c 2024 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1734529954_1200 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background and Objective: Nutrimetabolomics may reveal novel insights into early metabolic alterations and the role of dietary exposures on prostate cancer (PCa) risk. We aimed to prospectively investigate the associations between plasma metabolite concentrations and PCa risk, including clinically relevant tumor subtypes. Methods: We used a targeted and large-scale metabolomics approach to analyze plasma samples of 851 matched PCa case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Associations between metabolite concentrations and PCa risk were estimated by multivariate conditional logistic regression analysis. False discovery rate (FDR) was used to control for multiple testing correction. Results: Thirty-one metabolites (predominately derivatives of food intake and microbial metabolism) were associated with overall PCa risk and its clinical subtypes (p < 0.05), but none of the associations exceeded the FDR threshold. The strongest positive and negative associations were for dimethylglycine (OR = 2.13; 95% CI 1.16-3.91) with advanced PCa risk (n = 157) and indole-3-lactic acid (OR = 0.28; 95% CI 0.09-0.87) with fatal PCa risk (n = 57), respectively; however, these associations did not survive correction for multiple testing. Conclusions: The results from the current nutrimetabolomics study suggest that apart from early metabolic deregulations, some biomarkers of food intake might be related to PCa risk, especially advanced and fatal PCa. Further independent and larger studies are needed to validate our results. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a EPIC |2 Other |
| 650 | _ | 7 | |a nested case–control |2 Other |
| 650 | _ | 7 | |a nutrimetabolomics |2 Other |
| 650 | _ | 7 | |a prostate cancer |2 Other |
| 700 | 1 | _ | |a Martínez-Huélamo, Miriam |0 0000-0002-7650-4016 |b 1 |
| 700 | 1 | _ | |a López-Hernández, Yamilé |b 2 |
| 700 | 1 | _ | |a Guiñón-Fort, Daniel |b 3 |
| 700 | 1 | _ | |a Guadall, Anna |0 0000-0002-7821-8582 |b 4 |
| 700 | 1 | _ | |a Cruz, Meryl |0 0000-0002-8327-4220 |b 5 |
| 700 | 1 | _ | |a Perez-Cornago, Aurora |b 6 |
| 700 | 1 | _ | |a Rostgaard-Hansen, Agnetha L |0 0000-0001-5731-1772 |b 7 |
| 700 | 1 | _ | |a Tjønneland, Anne |0 0000-0003-4385-2097 |b 8 |
| 700 | 1 | _ | |a Dahm, Christina C |0 0000-0003-0481-2893 |b 9 |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 10 |u dkfz |
| 700 | 1 | _ | |a Schulze, Matthias B |0 0000-0002-0830-5277 |b 11 |
| 700 | 1 | _ | |a Masala, Giovanna |0 0000-0002-5758-9069 |b 12 |
| 700 | 1 | _ | |a Agnoli, Claudia |b 13 |
| 700 | 1 | _ | |a Tumino, Rosario |0 0000-0003-2666-414X |b 14 |
| 700 | 1 | _ | |a Ricceri, Fulvio |0 0000-0001-8749-9737 |b 15 |
| 700 | 1 | _ | |a Lasheras, Cristina |0 0000-0003-0482-4229 |b 16 |
| 700 | 1 | _ | |a Crous-Bou, Marta |b 17 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |0 0000-0003-4817-0757 |b 18 |
| 700 | 1 | _ | |a Aizpurua-Atxega, Amaia |b 19 |
| 700 | 1 | _ | |a Guevara, Marcela |0 0000-0001-9242-6364 |b 20 |
| 700 | 1 | _ | |a Tsilidis, Kostas K |0 0000-0002-8452-8472 |b 21 |
| 700 | 1 | _ | |a Chatziioannou, Anastasia Chrysovalantou |0 0000-0002-1973-7542 |b 22 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 23 |
| 700 | 1 | _ | |a Travis, Ruth C |b 24 |
| 700 | 1 | _ | |a Wishart, David S |0 0000-0002-3207-2434 |b 25 |
| 700 | 1 | _ | |a Andrés-Lacueva, Cristina |0 0000-0002-8494-4978 |b 26 |
| 700 | 1 | _ | |a Zamora-Ros, Raul |0 0000-0002-6236-6804 |b 27 |
| 773 | _ | _ | |a 10.3390/cancers16234116 |g Vol. 16, no. 23, p. 4116 - |0 PERI:(DE-600)2527080-1 |n 23 |p 4116 |t Cancers |v 16 |y 2024 |x 2072-6694 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:295915 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-07-31T16:07:06Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-07-31T16:07:06Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-07-31T16:07:06Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-07-31T16:07:06Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-26 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|